^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SYN125
i
Other names: SYN125
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Synermore
Drug class:
PD1 inhibitor
Related drugs:
1year
A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions (clinicaltrials.gov)
P1, N=22, Active, not recruiting, Synermore Biologics Co., Ltd. | Recruiting --> Active, not recruiting | N=36 --> 22 | Trial completion date: May 2022 --> Sep 2023 | Trial primary completion date: Feb 2022 --> Jul 2023
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor)
|
SYN004 • SYN125
over3years
A Study to Find the Maximum Tolerated Dose (MTD) of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People With Cancer of the Internal or External Lining of the Body. (clinicaltrials.gov)
P1, N=36, Recruiting, Synermore Biologics Co., Ltd. | Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Sep 2021 --> Feb 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor)
|
SYN004 • SYN125
Share via
